# Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Canonical URL: https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-pricing-of-375-million-public-offering
Ticker: AVTX
Company: Avalo Therapeutics
Source: Avalo Therapeutics
Published: 2026-05-06 03:33 EST
Original Source URL: https://ir.avalotx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-22 20:01 EST — [Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4) — Source: Avalo Therapeutics
- 2026-05-13 11:00 EST — [Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-updates) — Source: Avalo Therapeutics
- 2026-05-06 03:33 EST — [Avalo Therapeutics Announces Pricing of $375 Million Public Offering](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-pricing-of-375-million-public-offering) — Source: Avalo Therapeutics
- 2026-05-05 20:05 EST — [Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants) — Source: Avalo Therapeutics
- 2026-05-05 20:01 EST — [Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-achieves-positive-topline-results-in-phase-2-lotus-trial-of-abdakibart-avtx-009-in-moderate-to-severe-hidradenitis-suppurativa) — Source: Avalo Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)